Deltito J A, Argyle N, Klerman G L
Anxiety and Depression Clinic, Cornell University Medical College, New York Hospital, White Plains 10605.
J Clin Psychiatry. 1991 Mar;52(3):121-7.
Patients with panic disorder (N = 1168) were enrolled in a multicenter, 8-week, double-blind clinical trial of imipramine, alprazolam, and placebo to analyze whether the effectiveness of these agents is dependent on the depressive/dysphoric symptomatology which often coexists in panic disorder patients. In addition to analyses performed on the whole sample of patients, the authors conducted analyses on a subsample (N = 312) defined by multiple criteria to ensure the absence of depression and dysphoria. In both the overall sample and the nondepressed subsample, the clinical response to imipramine or alprazolam was found to be independent of the presence of depression or dysphoria. In panic disorder patients for whom pharmacotherapy is being considered as treatment, the absence of depression is apparently not a contraindication.
惊恐障碍患者（N = 1168）被纳入一项多中心、为期8周的丙咪嗪、阿普唑仑和安慰剂双盲临床试验，以分析这些药物的有效性是否取决于惊恐障碍患者中常并存的抑郁/烦躁症状。除了对全体患者样本进行分析外，作者还对通过多项标准定义的一个子样本（N = 312）进行了分析，以确保不存在抑郁和烦躁情绪。在总体样本和无抑郁子样本中，均发现对丙咪嗪或阿普唑仑的临床反应与抑郁或烦躁情绪的存在无关。对于考虑采用药物治疗的惊恐障碍患者，不存在抑郁显然不是一个禁忌证。
